<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">121897</article-id><article-id pub-id-type="doi">10.23868/202205006</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Expression profile of the microenvironment of morphological structures in luminal breast cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Экспрессионный профиль микроокружения морфологических структур люминального рака молочной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tashireva</surname><given-names>L. A</given-names></name><name xml:lang="ru"><surname>Таширева</surname><given-names>Л. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gerashchenko</surname><given-names>T. S</given-names></name><name xml:lang="ru"><surname>Геращенко</surname><given-names>Т. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zolotareva</surname><given-names>S. Yu</given-names></name><name xml:lang="ru"><surname>Золотарева</surname><given-names>С. Ю</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Perelmuter</surname><given-names>V. M</given-names></name><name xml:lang="ru"><surname>Перельмутер</surname><given-names>В. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Cancer Research Institute, Tomsk National Research Medical Center of the RAS</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2022</year></pub-date><volume>17</volume><issue>1</issue><issue-title xml:lang="en">VOL 17, NO1 (2022)</issue-title><issue-title xml:lang="ru">ТОМ 17, №1 (2022)</issue-title><fpage>31</fpage><lpage>37</lpage><history><date date-type="received" iso-8601-date="2023-01-16"><day>16</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Эко-Вектор</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-03-15"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/121897">https://genescells.ru/2313-1829/article/view/121897</self-uri><abstract xml:lang="en"><p>In breast cancer, the predictive value of tumor microenvironment parameters differs depending on the molecular subtype. Multidirectional significance may be reflection of heterogeneity of invasive breast carcinoma and requires further study. Significance of the tumor microenvironment in the formation and determination of the properties of various morphological structures is still not fully understood. The aim of the study is to determine the differences in the expression profile of the microenvironment of various morphological structures of breast cancer. 84 patients with breast cancer (T1-3N0-3M0) were included in the study of tumor-infiltrating lymphocytes level in microenvironment of different morphological structures. Microdissected samples of the microenvironment of different morphological structures sequenced using NextSeq500 (Illumina). CIBERSORT analysis was performed to deciphered the cellular composition of the microenvironment of each type of the structures. The microenvironment of all morphological structures was quite diverse in terms of cellular composition. The microenvironment of the single tumor cells exhibits pronounced pro-tumor properties, including expression of the IL1B gene, activation of inflammatory signaling pathways, increased signature of M2 macrophages. The results shown the role of the microenvironment of single tumor cells in breast cancer distant metastasis.</p></abstract><trans-abstract xml:lang="ru"><p>При раке молочной железы прогностическая ценность параметров микроокружения опухоли различается в зависимости от молекулярно-генетического подтипа опухоли. Такая разнонаправленная связь может быть отражением гетерогенности инвазивной карциномы молочной железы и требует дальнейшего изучения. Значение микроокружения опухоли в формировании и определении свойств различных морфологических структур всё еще до конца не изучено. Цель исследования: определить различия в экспрессионном профиле микроокружения различных морфологических структур рака молочной железы. В исследование были включены 84 больных раком молочной железы (T1_3N0_3M0). Образцы тканей микроокружения опухоли различных типов морфологических структур были получены с помощью лазерной микродиссекции (PALM, Zeiss). Секвенирование проводили на приборе NextSeq500 (Illumina). Для определения клеточного состава микроокружения опухоли каждого типа морфологических структур был проведен CIBERSORT анализ. Микроокружение опухоли у всех типов морфологических структур разнообразно по клеточному составу. Микроокружение одиночных опухолевых клеток проявляет выраженные проопухолевые свойства, включая экспрессию гена IL1B, активацию воспалительных сигнальных путей и усиление сигнатуры макрофагов М2. Полученные результаты могут свидетельствовать о роли микроокружения одиночных опухолевых клеток в развитии гематогенных метастазов рака молочной железы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>tumor microenvironment</kwd><kwd>morphological heterogeneity</kwd><kwd>bulk sequencing</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>микроокружение опухоли</kwd><kwd>морфологическая гетерогенность</kwd><kwd>секвенирование</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Таширева Л.А., Перельмутер В.М., Манских В.Н. и соавт. Типы иммуновоспалительных реакций как алгоритмы взаимодействия клеток в условиях репаративной регенерации и опухолевого роста. Биохимия 2017; 82(5): 732-48.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zitvogel L., Galluzzi L., Kepp O. et al. Type I. interferons in anticancer immunity. Nat. Rev. Immunol. 2015; 15(7): 405-14.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Tan A.H., Goh S.Y., Wong S.C. et al. T. helper cell-specific regulation of inducible costimulator expression via distinct mechanisms mediated by T-bet and GATA-3. J. Biol. Chem. 2008; 283(1): 128-36.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gao Z.H., Li C.X., Liu M. et al. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer 2020; 20(1): 1150.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Таширева Л.А., Ляпунова Л.С., Бузенкова А.В. и соавт. Прогностическая значимость количества опухоль-инфильтрирующих лимфоцитов при различных молекулярных подтипах рака молочной железы. Гены и Клетки 2020; 15(2): 89-95.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Denisov E.V., Skryabin N.A., Gerashchenko T.S. et al. Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44+CD24- stemness. Oncotarget 2017; 8(37): 61163-80.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Zavyalova M.V., Denisov E.V., Tashireva L.A. et al. Phenotypic drift as a cause for intratumoral morphological heterogeneity of invasive ductal breast carcinoma not otherwise specified. Biores. Open Access 2013; 2(2): 148-54.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kos Z., Roblin E., Kim R.S. et al. International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer 2020; 6: 17.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Dobin A., Davis C.A., Schlesinger F. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29(1): 15-21.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Liao Y., Smyth G.K., Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30(7): 923-30.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chen B., Khodadoust M.S., Liu C.L. et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol. Biol. 2018; 1711: 243-59.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Tashireva L.A., Zavyalova M.V., Savelieva O.E. et al. Single Tumor Cells With Epithelial-Like Morphology Are Associated With Breast Cancer Metastasis. Front. Oncol. 2020; 10: 50.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Munger J.S., Huang X., Kawakatsu H. et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96(3): 319-28.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Eyre R., Alferez D.G., Santiago-Gomez A. et al. Microenvironmental IL1 p promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat. Commun. 2019; 10(1): 5016.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Lu X., Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J. Biol. Chem. 2009; 284(42): 29087-96.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pollard J.W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 2008; 84(3): 623-30.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Gyorki D.E., Asselin-Labat M.L., van Rooijen N. et al. Resident macrophages influence stem cell activity in the mammary gland. Breast Cancer Res. 2009; 11(4): R62.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Oldford S.A., Marshall J.S. Mast cells as targets for immunotherapy of solid tumors. Mol. Immunol. 2015; 63(1): 113-24.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Piconese S., Gri G., Tripodo C. et al. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 2009; 114(13): 2639-48.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Dudeck A., Dudeck J., Scholten J. et al. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 2011; 34(6): 973-84.</mixed-citation></ref></ref-list></back></article>
